Abbott Laboratories (Pakistan) (KAR:ABOT) Cyclically Adjusted Revenue per Share: ₨527.98 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KAR:ABOT Abbott Laboratories (Pakistan) Ltd KAR:ABOT
76 GF Score
Price ₨916.87
GF Value ₨1,012.45
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Abbott Laboratories (Pakistan) Cyclically Adjusted Revenue per Share?

Abbott Laboratories (Pakistan) KAR:ABOT -0.81% 76 Cyclically Adjusted Revenue per Share is ₨527.98 as of Mar. 2026. GuruFocus rates KAR:ABOT with a GF Score™ of 76/100 and a GF Value™ of ₨1,012.45 (Fairly Valued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Abbott Laboratories (Pakistan)'s adjusted revenue per share for the three months ended in Mar. 2026 was ₨180.852. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₨527.98 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Abbott Laboratories (Pakistan)'s average Cyclically Adjusted Revenue Growth Rate was 13.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 13.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Abbott Laboratories (Pakistan) was 13.50% per year. The lowest was 13.50% per year. And the median was 13.50% per year.

As of today (2026-07-24), Abbott Laboratories (Pakistan)'s current stock price is ₨916.87. Abbott Laboratories (Pakistan)'s Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ₨527.98. Abbott Laboratories (Pakistan)'s Cyclically Adjusted PS Ratio of today is 1.74.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Abbott Laboratories (Pakistan) was 2.87. The lowest was 0.90. And the median was 1.79.


Abbott Laboratories (Pakistan)  (KAR:ABOT) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Abbott Laboratories (Pakistan)'s Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=916.87/527.98
=1.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Abbott Laboratories (Pakistan) was 2.87. The lowest was 0.90. And the median was 1.79.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Abbott Laboratories (Pakistan) Cyclically Adjusted Revenue per Share Related Terms


Abbott Laboratories (Pakistan) Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Abbott Laboratories (Pakistan)'s Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abbott Laboratories (Pakistan) Cyclically Adjusted Revenue per Share Chart

Abbott Laboratories (Pakistan) Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 347.17 392.99 447.44 507.18

Abbott Laboratories (Pakistan) Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 465.20 481.04 497.00 507.18 527.98

KAR:ABOT vs ZTS, UTHR, VTRS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Abbott Laboratories (Pakistan)'s Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abbott Laboratories (Pakistan) Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Abbott Laboratories (Pakistan)'s Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Abbott Laboratories (Pakistan)'s Cyclically Adjusted PS Ratio falls into.


KAR:ABOT
76GF Score
Abbott Laboratories (Pakistan) Ltd KAR:ABOT
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abbott Laboratories (Pakistan) Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Abbott Laboratories (Pakistan)'s adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=180.852/330.2130*330.2130
=180.852

Current CPI (Mar. 2026) = 330.2130.

Abbott Laboratories (Pakistan) Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 62.087 241.018 85.064
201609 59.460 241.428 81.326
201612 67.375 241.432 92.151
201703 55.112 243.801 74.646
201706 68.053 244.955 91.739
201709 67.457 246.819 90.249
201712 75.848 246.524 101.597
201803 64.731 249.554 85.653
201806 76.016 251.989 99.613
201809 79.797 252.439 104.382
201812 83.026 251.233 109.127
201903 73.772 254.202 95.831
201906 82.808 256.143 106.754
201909 71.115 256.759 91.460
201912 80.383 256.974 103.293
202003 82.342 258.115 105.342
202006 86.571 257.797 110.889
202009 86.229 260.280 109.397
202012 105.337 260.474 133.540
202103 101.000 264.877 125.913
202106 111.414 271.696 135.410
202109 108.790 274.310 130.961
202112 113.629 278.802 134.582
202203 120.261 287.504 138.126
202206 131.675 296.311 146.740
202209 125.372 296.808 139.482
202212 125.701 296.797 139.854
202303 140.877 301.836 154.121
202306 137.421 305.109 148.728
202309 146.715 307.789 157.404
202312 145.395 306.746 156.518
202403 163.692 312.332 173.063
202406 165.251 314.175 173.687
202409 177.376 315.301 185.765
202412 190.122 315.605 198.922
202503 177.187 319.799 182.957
202506 194.684 322.561 199.302
202509 202.482 324.800 205.856
202512 195.798 324.054 199.519
202603 180.852 330.213 180.852

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₨527.98 mean?
Abbott Laboratories (Pakistan) (KAR:ABOT) has a Cyclically Adjusted Revenue per Share of ₨527.98 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Abbott Laboratories (Pakistan) and its competitors.
Is Abbott Laboratories (Pakistan)'s Cyclically Adjusted Revenue per Share too high?
Abbott Laboratories (Pakistan)'s current Cyclically Adjusted Revenue per Share is ₨527.98. Overall, Abbott Laboratories (Pakistan) has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Abbott Laboratories (Pakistan)'s Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Abbott Laboratories (Pakistan)'s Cyclically Adjusted Revenue per Share of ₨527.98 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Abbott Laboratories (Pakistan) and its competitors. Abbott Laboratories (Pakistan)'s current Cyclically Adjusted Revenue per Share is ₨527.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbott Laboratories (Pakistan) stock overvalued right now?
Based on GuruFocus' analysis, Abbott Laboratories (Pakistan) (KAR:ABOT) is currently considered Fairly Valued. The stock's GF Value™ is ₨1,012.45, compared to a current price of ₨916.87 — trading 9.4% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₨527.98. Abbott Laboratories (Pakistan)'s overall GF Score™ is 76/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Abbott Laboratories (Pakistan) (KAR:ABOT), the current Cyclically Adjusted Revenue per Share is ₨527.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Abbott Laboratories (Pakistan) (KAR:ABOT) Overvalued in 2026?

Based on GuruFocus' analysis, Abbott Laboratories (Pakistan) stock appears to be undervalued. The current stock price of ₨916.87 is trading 9.4% below its estimated GF Value™ of ₨1,012.45. GuruFocus considers Abbott Laboratories (Pakistan) to be Fairly Valued.

Key valuation signals for KAR:ABOT:

  • Cyclically Adjusted Revenue per Share: ₨527.98
  • GF Value™: ₨1,012.45 vs. price of ₨916.87 (9.4% below fair value)
  • GF Score™: 76/100 with 2 warning signs

No single metric tells the full story. See the KAR:ABOT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Abbott Laboratories (Pakistan) Business Description

Address Hyderabad Road, Landhi, P.O. Box 7229, Plot No. 258 & 324, Opposite Radio Pakistan Transmission Centre, Karachi, PAK, 75120
Abbott Laboratories (Pakistan) Ltd manufactures, imports, and markets research-based pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital, and consumer products. Its operating segments are Pharmaceutical, Nutritional, Diagnostics, and Others. It generates maximum revenue from the Pharmaceutical segment. Geographically, it derives the majority of its revenue from Pakistan and has a presence in Afghanistan, Sri Lanka, Bangladesh, and Switzerland. The company's Brands include Duphaston, Brufen, Surbex Z, Arinac, Glucerna, Pediasure, and Ensure.
76GF Score

Get the complete analysis for KAR:ABOT

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₨916.87
Price
₨1,012.45
GF Value